Encoberminogene rezmadenovec is under clinical development by XyloCor Therapeutics and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease). According to GlobalData, Phase II drugs for Coronary Artery Disease (CAD) (Ischemic Heart Disease) have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Encoberminogene rezmadenovec’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Encoberminogene rezmadenovec overview
XC-001 is under development for the treatment of coronary heart disease and refractory angina. It is administered directly to ischemic myocardium. It is an Ad5 vector expressing the cDNA/genomic hybrid of the vascular endothelial growth factor (VEGF) gene (expressing isoforms, 121, 165 and 189).
XyloCor Therapeutics overview
XyloCor Therapeutics (XyloCor) is a biopharmaceutical company that offers development of gene therapy for cardiovascular diseases. The company’s portfolio of pipeline products includes XC001 and XC002. It develops its products for the treatment of refractory angina and for regeneration of cardiac tissue. The company’s XC001 is designed to stimulate the formation of new coronary blood vessels to serve areas of the heart that are not receiving adequate blood supply. It serves patients with refractory angina. XyloCor Therapeutics is headquartered in Newtown Square, Pennsylvania, the US.
For a complete picture of Encoberminogene rezmadenovec’s drug-specific PTSR and LoA scores, buy the report here.